BiotechTube

Volitinib

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Food Effect

Conditions

Food Effect, Health Subjects

Trial Timeline

Nov 1, 2013 → Jun 1, 2014

NCT ID
NCT02017236

About Volitinib

Volitinib is a phase 1 stage product being developed by HUTCHMED for Food Effect. The current trial status is completed. This product is registered under clinical trial identifier NCT02017236. Target conditions include Food Effect, Health Subjects.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT02017236Phase 1Completed
NCT01773018Phase 1Completed

Competing Products

17 competing products in Food Effect

See all competitors
ProductCompanyStageHype Score
Milademetan Treatment A + Milademetan Treatment B + Milademetan Treatment CDaiichi SankyoPhase 1
33
E7386EisaiPhase 1
33
AZD7986, oral solution, 1 to 50 mg/mL + Placebo, oral solutionAstraZenecaPhase 1
33
AcalabrutinibAstraZenecaPhase 2
52
esomeprazole/ASA Fixed Dose Combination (FDC)AstraZenecaPhase 1
33
Ligelizumab 120 mg + Ligelizumab 240 mgNovartisPhase 3
77
OmalizumabNovartisApproved
85
Omalizumab InjectionRocheApproved
85
Glucopyranosyl Lipid A (GLA) + Sublingual Immuno Therapy (SLIT) Peanut Extract (PE) + Placebo for GLA + Placebo for SLIT PESanofiPhase 1
32
DupilumabRegeneron PharmaceuticalsPre-clinical
22
linvoseltamab + dupilumabRegeneron PharmaceuticalsPhase 1
32
DupilumabRegeneron PharmaceuticalsPhase 2
51
Sativex + Sativex + Sativex + SativexJazz PharmaceuticalsPhase 1
30
fruquintinibHUTCHMEDPhase 1
28
Viaskin Milk 150 mcg + Viaskin Milk 300 mcg + Viaskin Milk 500 mcg + Viaskin PlaceboDBV TechnologiesPhase 1/2
36
AZD1722 salt tablet + AZD1722 free base tablet + AZD1722 free base tablet + OmeprazoleArdelyxPhase 1
28
E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3Allergy TherapeuticsPhase 1
28

Other Products from HUTCHMED

fruquintinib + sintilimab + paclitaxel + doxorubicinPhase 3
72
fruquintinib + placeboPhase 3
72
Fruquintinib + PlaceboPhase 3
72
HMPL-760 + HMPL-760 Placebo + R-GemOxPhase 3
72
SurufatinibPhase 3
72